RedHill Biopharma (RDHL) Current Leases (2019 - 2025)

RedHill Biopharma (RDHL) has 7 years of Current Leases data on file, last reported at $170000.0 in Q4 2025.

• On a quarterly basis, Current Leases fell 51.84% year-over-year to $170000.0 in Q4 2025; TTM through Dec 2025 was $170000.0, a 51.84% decrease from a year earlier, with the FY2025 full-year figure at $170000.0, down 51.84% from the prior year.
• Current Leases for Q4 2025 stood at $170000.0, down from $353000.0 in the prior quarter.
• Over the last five years, Current Leases for RDHL reached as high as $1.6 million in Q4 2021 and fell as low as $170000.0 in Q4 2025.
• Historically, Current Leases has averaged $778200.0 across 5 years, with a median of $718000.0 in 2023.
• Across the five-year window, Current Leases retreated 5.38% in 2021 and plunged 51.84% in 2025, its largest moves.
• Year by year, Current Leases stood at $1.6 million in 2021, then sank by 36.22% to $1.0 million in 2022, then slumped by 30.43% to $718000.0 in 2023, then plunged by 50.84% to $353000.0 in 2024, then tumbled by 51.84% to $170000.0 in 2025.
• Per Business Quant data, the three most recent Current Leases figures were $170000.0 in Q4 2025, $353000.0 in Q4 2024, and $718000.0 in Q4 2023.